Duan, Likun
Cooper, Daniel E.
Scheidemantle, Grace
Locasale, Jason W.
Kirsch, David G.
Liu, Xiaojing http://orcid.org/0000-0002-4231-6017
Funding for this research was provided by:
Duke Cancer Institute Pilot Grant (P30CA014236)
Foundation for the National Institutes of Health (R35CA197616)
National Institutes of Health (T32CA093240)
Article History
Received: 22 March 2021
Accepted: 16 June 2022
First Online: 7 July 2022
Declarations
:
: All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Duke University.
: All authors have read and approved the manuscript.
: DGK is a cofounder of the XRAD Therapeutics, which is developing radiosensitizers. DGK is on the scientific advisory board of the Lumicell, which is developing intraoperative imaging technology. DGK is a recipient of a Stand Up To Cancer (SU2C) Merck Catalyst Grant studying pembrolizumab and radiation therapy in sarcoma patients. DGK has received research funding and/or reagents from the XRAD Therapeutics, Merck, Amgen, Bristol Myers Squibb, Varian Medical Systems, and Calithera. These interests are outside the scope of the current manuscript. The other authors declare that they have no competing interests.